This analysis shows that hardship and not hardship cases respectively reject clear differences both at the demand and at the expenditures for pharmaceuticals financed by the statutory health insurance. Hardship cases without exemption regulations would be burden therefore by enormous co-payments. Moreover, it also turns out that straight hardship cases are less healthy on average than not hardship cases. Co-payments without accompanying hardship case regulations would therefore hardly make a supply possible adapted to the needs of hardship cases. On the other hand the effectivity of drug co-payment regulations is reduced by hardship case regulations considerably.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
Publisher Info
Paper provided by Universitaet Augsburg, Institute for Economics in its series Discussion Paper Series with number
285.
Find related papers by JEL classification: I10 - Health, Education, and Welfare - - Health - - - General I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
This paper has been announced in the following NEP Reports: